ALK to Ring The Nasdaq Stock Market Closing Bell

ADVISORY, Dec. 30, 2015 (GLOBE NEWSWIRE) --  

What: 

ALK, a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment, will visit the Nasdaq MarketSite in Times Square.

In honor of the occasion, Jens Bager, President and CEO of ALK, will ring the Closing Bell. 

Where:

Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio

When:

Thursday, December 31st, 2015 – 3:45 p.m. to 4:00 p.m. ET

ALK Media Contact:Jeppe Ilkjær+45 3050 2014[email protected]

Nasdaq MarketSite:Emily Pan(646) 441-5120[email protected]

Feed Information:

Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West18 mhz LowerDL 3811 VerticalFEC 3/4SR 13.235DR 18.295411MOD 4:2:0DVBS QPSK

Social Media:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:

http://www.facebook.com/NASDAQ.

For photos from ceremonies and events visit our Instagram Page:

http://instagram.com/nasdaq

For news tweets, please visit our Twitter page at:

http://twitter.com/nasdaq

For exciting viral content and ceremony photos visit Tumblr Page:

http://nasdaq.tumblr.com/

Webcast:

A webcast of the Nasdaq Closing Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos: 

To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.

About ALK

ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is a world leader in allergy immunotherapy – a treatment of the underlying cause of allergy. The company has approximately 1,900 employees, with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with MSD (known as Merck in the USA and Canada), Torii, Abbott and Seqirus (prev. bioCSL) to commercialise sublingual allergy immunotherapy tablets in North America, Japan, Russia, Australia and New Zealand, respectively. The company is headquartered in Hørsholm, Denmark, and listed on NASDAQ Copenhagen. Find more information at www.alk.net.

About Nasdaq:

Nasdaq (Nasdaq: NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,600 listed companies with a market value of approximately $8.8 trillion and more than 10,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.

 -NDAQA-

 

Source: NASDAQ, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Nasdaq Announces Definitive Agreement to Acquire LeveL Markets, Advancing Nasdaq’s Always-On Markets Strategy
• KULR Technology Group Reports Second Quarter 2026 Financial Results
• Nektar Therapeutics Announces Second Quarter 2026 Financial Results